T.I. KHAIBULLIN^1,2, N.N. BABICHEVA¹, G.M. AKHMEDOVA², L.A. AVERIANOVA¹, E.V. GRANATOV¹, S.R. SHAKIRZANOVA¹

¹Republic Clinical-diagnostic Center for Demyelinating Diseases, 13 Vatutin Str., Kazan, Russian Federation, 420021

²Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, 36 Butlerov Str., 420012 Kazan, Russian Federation

 Khaybullin T.I. — PhD (medicine), Associate Professor of the Department of Neurology and Manual Therapy, neurologist, tel. (843) 278-23-17, e-mail: timuur@gmail.com, ORCID ID: 0000-0002-5009-6683

Babicheva N.N. — neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0001-5562-5065

Akhmedova G.M. — PhD (medicine), Associate Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0003-0857-8934

Granatov E.V. — PhD (medicine), neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0002-0589-3288

Averianova L.A. — PhD (medicine), neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0003-2825-9041

Shakirzanova S.R. — neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0003-2252-2259

Objective ― to study the modern publications on the key pathogenetic mechanisms of multiple sclerosis and modern possibilities of targeted therapeutic impacts on them.

Material and methods. Data of 12 scientific articles published from 2008 to 2018 in PubMed and the «Multiple Sclerosis Journal» journal were analyzed.

Results and conclusions. In the pathogenesis of multiple sclerosis (MS), several key mechanisms of development and progression of the disease are identified. Currently, there are many means of specific disease-modifying drugs (DMD), affecting various pathogenetic mechanisms of the disease. Some DMDs have several points of impacts, others DMDs have target effects. Careful consideration of the clinical picture and course of the disease, neuroimaging indicators and, possibly, biomarkers of the cerebrospinal fluid allows a more reasonable approach to the choice of the drug for the basic therapy of MS.

Key words: multiple sclerosis, pathogenesis, treatment, disease-modifying drugs.

(For citation: Khaybullin T.I., Babicheva N.N., Akhmedova G.M., Granatov E.V., Averianova L.A., Shakirzanova S.R. Key pathogenetic mechanisms of multiple sclerosis and the possibilities of target inthem: state of the problem. Practical Medicine. 2018)